**CAR –T Symposium dinsdag 9 november**

Innovaties in Cellulaire Therapie

13.00 Opening dagvoorzitter

13.30 Liso-Cel for DLBCL **- Pim Mutsaers**, Rotterdam

13.50 New indications for CD19 CAR T-cells: FL and MCL – **Marie José Kersten**, Amsterdam

14.10 CD19 CAR T-cell therapy for DLBCL and ALL: real world data in the Netherlands – **Tom van Meerten**, Groningen & **Friso Calkoen**, Utrecht

14:30 Break

14:45 ZUMA-3 trial for adults with ALL – **Lotte van de Wagen**, Utrecht

15:05 Bridging with blinatumomab or inotuzumab before anti-CD19 CAR T cell therapy - pros en cons - André Baruchel

15:25 Panel discussion: Practical points on bridging therapies in ALL and DLBCL and post CART consolidation therapies in ALL

* Chairperson: **Monique Minnema** (stellingen maken)
* Panel: van Meerten, van de Wagen, Baruchel, Vormoor

15.45 Break

16:00 Antigen-specific T cell receptors as a promising therapeutic tool

– **Mirjam Heemskerk**, Leiden

16.20 Keynote lecture 1:

CAR T cells for high grade gliomas and mechanisms of resistance in hematologic malignancies

- **Christal Mackall**

17:05 Keynote lecture 2:

CAR T cell development for neuroblastoma – **John Anderson**, London

17:50 Closing remarks

**Backups:**

* CAR T cells for multiple myeloma - Michael Hudecek, Wurzburg)
* In vitro imaging of TEC cells: new insights in cellular immune-targeting – Anne Rios, Utrecht